Working… Menu

Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00650949
Recruitment Status : Terminated (Strategic)
First Posted : April 2, 2008
Last Update Posted : May 3, 2013
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
This study seeks to (i) determine the safe dose of CYT997 when given in combination with carboplatin in patients with relapsed glioblastoma multiforme (glioma) and (ii) to determine whether the combination of CYT997 with carboplatin is a useful treatment for glioma.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: CYT997 Drug: Carboplatin Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II Study of CYT997 in Combination With Carboplatin in Relapsed Glioblastoma Multiforme
Study Start Date : November 2009
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Carboplatin

Arm Intervention/treatment
Experimental: CYT997 Drug: CYT997
Escalating doses (100mg/m^2 to 150mg/m^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.

Drug: Carboplatin
Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle

Primary Outcome Measures :
  1. Safety and tolerability of escalating doses of CYT997 when given in combination with standard carboplatin therapy (Phase Ib component) [ Time Frame: Ongoing throughout therapy up until 30 days after last dose of CYT997 ]
  2. Progression-free survival at 6 months (PFS-6) utilising the dose of CYT997 identified in the Phase Ib component of this study (Phase II component) [ Time Frame: 6 months after initiation of therapy ]

Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Response is measured every second cycle of therapy ]
  2. Overall survival [ Time Frame: Baseline to study completion ]
  3. Safety and tolerability [ Time Frame: Measured continuously from study commencement through to 30 days after last dose of CYT997 ]
  4. Effects on pharmacodynamic markers of vascular disruption and tumour apoptosis [ Time Frame: Measured during first cycle of therapy ]
  5. Pharmacokinetic analysis of carboplatin and CYT997 in combination [ Time Frame: Assessed during first cycle of therapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically-confirmed glioblastoma multiforme that has progressed after initial surgery, radiation therapy and temozolomide chemotherapy.
  • Measurable tumour must be present on gadolinium-enhanced MRI
  • At least 3 months must have elapsed from completing radiation to minimize the possibility of pseudo-progression.
  • At least 4 weeks since prior chemotherapy (6 weeks if the last regimen included bischloroethylnitrosourea (BCNU) or Chloroethyl-Cyclohexyl-NitrosoUrea (CCNU)).
  • Age ≥ 18 years.
  • If patients are taking steroids, the dose must be stable for = 7 days.
  • Eastern Cooperative Oncology Group (ECOG) performance status = 2.
  • Life expectancy of greater than 2 months.
  • Patients must have adequate organ and marrow function as defined below:

    • Absolute neutrophil count = 1.5 × 109/L
    • Platelet count = 100 × 109/L
    • Total bilirubin within normal limits
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 5 × upper limit of normal (ULN)
    • Creatinine within normal limits OR creatinine clearance = 60 mL/min/1.73 m2 for patients with creatinine levels above normal
    • Normal left ventricular ejection fraction on a gated blood pool scan or echocardiogram
  • Must agree to use adequate contraceptive measures if indicated
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have received any other investigational agent in the preceding four weeks prior to commencing therapy in this study.
  • Patients who have been previously treated with carboplatin.
  • Patients who have been previously treated with bevacizumab or other anti-angiogenesis or vascular-disrupting agents
  • Patients who are receiving enzyme-inducing anticonvulsant drugs (EIACD) such as phenytoin or carbamazepine.
  • Patients with a history of allergic reactions attributed to compounds of similar chemical composition to CYT997 or other agents used in the study.
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or lactating women.
  • Patients with immune deficiency, including HIV-positive patients.
  • Patients with uncontrolled diarrhoea despite optimal medication and those with any history of acute gastrointestinal bleeding.
  • Patients who are unable or unwilling to undergo MRI scanning
  • Patients with the following conditions/treatments will be excluded:

    • Myocardial infarction (MI) or stroke within 6 months
    • History of stroke or transient ischemic attacks (TIAs)
    • Unstable angina pectoris or acute ischemic changes on ECG
    • History of diabetic retinopathy
    • Symptomatic peripheral arterial disease o Major surgery in the last 4 weeks
    • Evidence of intra-tumoural haemorrhage on imaging, except for stable grade-1 post-operative haemorrhage.
    • Current therapeutic anti-coagulation with warfarin or a heparin (excludes lowdose prophylactic heparin).
    • Uncontrolled hypertension
    • The need for any anti-arrhythmic drugs
  • Presence of luminal stenosis of 50% or more in any of the extracranial or intracranial arteries supplying the brain, as measured by magnetic resonance angiography (MRA) at baseline.
  • Patients with a baseline prolongation of the QTc interval of Common Terminology Criteria (CTC) grade 1 (QTc > 0.45- 0.47 sec) or greater.
  • Patients with impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

    • Left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram;
    • complete left bundle branch block;
    • obligate use of a cardiac pacemaker;
    • congenital long QT syndrome;
    • history or presence of ventricular tachyarrhythmia;
    • presence of unstable atrial fibrillation (ventricular response > 100 bpm) Patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria;
    • clinically significant resting bradycardia (< 50 bpm);
    • right bundle branch block + left anterior hemiblock (bifascicular block);
    • angina pectoris = 3 months prior to starting study drug;
    • acute MI = 3 months prior to starting study drug; or
    • other clinically significant heart disease (e.g., congestive heart failure (CHF), uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).
  • Patients currently receiving treatment with medications known to prolong the QTc interval and/or to induce Torsades de Pointes arrhythmia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00650949

Layout table for location information
Australia, New South Wales
Royal North Shore Hospital
St-Leonards, New South Wales, Australia, 2065
Australia, Queensland
Gold Coast Hospital
Southport, Queensland, Australia, 4215
Australia, South Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia, 5042
Australia, Victoria
Monash Medical Centre
Melbourne, Victoria, Australia, 3168
Sponsors and Collaborators
Gilead Sciences
Layout table for investigator information
Study Chair: Jason Lickliter, MD Peninsula Health
Principal Investigator: Helen Wheeler, MD Royal North Shore Hospital
Principal Investigator: Ganessan Kichenadasse, MD Flinders Medical Centre
Layout table for additonal information
Responsible Party: Gilead Sciences Identifier: NCT00650949    
Other Study ID Numbers: CCL08001
First Posted: April 2, 2008    Key Record Dates
Last Update Posted: May 3, 2013
Last Verified: April 2013
Keywords provided by Gilead Sciences:
Glioblastoma multiforme
Phase Ib/II
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents